Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on VMWARE INC-CLASS A. We currently have 0 research reports from 0 professional analysts.
|26Jan17 21:15||MKW||VMware Reports Fourth Quarter and Full Year 2016 Results|
|18Mar16 12:00||MKW||Karen Dykstra, Former AOL and ADP Chief Financial Officer, Joins VMware Board of Directors|
|16Feb16 21:10||MKW||VMware to Present at the Morgan Stanley Technology, Media and Telecom Conference|
|09Feb16 21:05||MKW||VMware Announces Changes to Board of Directors|
|26Jan16 21:15||MKW||VMware Reports Fourth Quarter and Full Year 2015 Results|
|12Jan16 21:02||MKW||VMware to Announce Fourth Quarter and Full Year 2015 Financial Results on Tuesday, January 26, 2016|
|23Nov15 13:00||MKW||OSIS Turns to VMware to Enhance Delivery of IT Services to Community Health Centers Nationwide|
Frequency of research reports
Research reports on
VMWARE INC-CLASS A
VMWARE INC-CLASS A
N+1 Singer - NCC Group - Further issues in Assurance
22 Feb 17
NCC released a trading update yesterday afternoon highlighting further issues in its Assurance division. Sales growth has been lower than expected in all regions, resulting in a significant reduction in full year expectations. We have reduced our EPS forecasts by 25% in FY’17 and 22%/25% in FY’18/’19 respectively. Escrow continues to perform in line with expectations. In response to these issues the Board has announced a strategic review into all of the Assurance businesses. The results of the strategic review are expected to be announced at the FY results in July. With an extended period of uncertainty on the horizon we believe it will be hard for investors to gain confidence in NCC in the short term. That said we see fundamental value in the stock. Escrow is unaffected by this warning and remains an extremely high quality business, which we value at £353m in our SOTP. At the current share price this leaves Assurance valued at c.5x cal’17 EBITDA. While this appears to be an attractive multiple for a rare cybersecurity asset, we would like further clarity on the underlying nature of the current issues, hence our Hold recommendation. Our 138p target price assumes a 12x EBITDA multiple for Assurance but we apply a 20% discount to the group to account for the current uncertainty.
21 Feb 17
Lighthouse Group* (LGT): Middle Britain growth (CORP) | Utilitywise* (UTW): Double-digit sales growth (CORP) | Trakm8* (TRAK): Earnings expectations cut again (CORP) | dotDigital* (DOTC): Myriad growth opportunities (CORP) | Artilium* (ARTA): Five-year Telenet deal secured and prepaid (CORP) | Netcall* (NET): Cloud investment pays off (CORP)
27 Feb 17
accesso expects full year profitability to be ahead of expectations. We have upgraded our Adj. PBT by 7% to $14.7m. The performance was achieved despite accelerated investment in “product and infrastructure to support business and growth opportunities in geographies outside its traditional core markets”. We see clear blue sky opportunity in the Asia-Pacific Market. We increase our T/P from 1850p to 1900p and maintain our Outperform recommendation.
N+1 Singer - dotdigital Group - Good H1; broadening avenues of growth
21 Feb 17
dotdigital delivered another good performance with H1’17 results showing 17% growth in revenues and 29% growth in PBT. Average monthly spend was up 24% as the group continues to move to the mid-market. We have made no changes to forecasts. Investments are being made to broaden its sources of growth both from a geographical and platform integration perspective. Additionally, the group flagged it is looking more closely at acquisitions that could accelerate its strategy. We believe the group remains well-placed to create further value with 81% recurring revenue, 3-yr EBITDA CAGR of 22%, £19m of net cash on the balance sheet, a positive demand environment and a track record of delivery.
N+1 Singer - IDOX - Positive AGM statement
24 Feb 17
Idox issued a positive AGM statement, indicating a strong start to the year, building on the performance and organic and acquisitive growth of 2016. It recently secured significant contracts in healthcare and transport and is continuing to win across other segments. The order book and pipeline, combined with a stable outlook across all its markets, support our positive view on the stock. We make no changes to our estimates which were recently upgraded for FY’16 results and the accretive 6PM acquisition. We believe the current 11.2x cal’17 EV/EBITDA rating is undemanding given its scale, profitability and outlook.
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced